Industry News
Biotechnology Industry News
Eikon Therapeutics is heading to…
Eikon Therapeutics is heading to the Nasdaq this morning with an upsized $381 million IPO in a further sign of the renewed appeal of the public markets.
As Eli Lilly awaits an FDA…
As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage drugs, including a gene therapy from its $1 billion acquisition of Prevail Therapeutics.
Novartis has nixed six early-stage…
Novartis has nixed six early-stage pipeline programs, swapping in two new phase 1 cancer candidates as replacements.
Stem cell therapy biotech PrimeGen…
Stem cell therapy biotech PrimeGen US is taking the less-traveled SPAC route to the public markets.
Luke Miels had only been at the…
Luke Miels had only been at the helm of GSK for 20 days when he signed off on his first multibillion-dollar buyout, and the CEO is clear on what else will attract his interest.
Novo Nordisk’s CEO was…
Novo Nordisk’s CEO was magnanimous about Pfizer’s victory in last year’s bidding war over an obesity biotech, but the Danish pharma is making no secret of the fact it remains on the lookout for a
Amgen’s bad luck in lupus may…
Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus erythematosus.
National Institutes of Health…
National Institutes of Health Director Jayanta Bhattacharya, M.D., Ph.D., spent much of a Senate committee hearing dancing around direct answers—except when it came to vaccines, a topic on which he finally delivered a clear view
While the Trump administration may…
While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.
Trial oversight is shifting from…
Trial oversight is shifting from reactive checks to continuous signal detection. Here’s the framework sponsors are adopting now.
As the first CAR-T treatment for…
As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDA’s Vinay Prasad, M.D., and colleagues have signaled a willingness to support the development of these novel cell therapies with a flexible
Pfizer has pumped the brakes on…
Pfizer has pumped the brakes on six early-stage assets, including three being tested in ulcerative colitis.
Exxel Pharma is eyeing a listing…
Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to deliver in the clinic.
Patients in a phase 2b trial kept…
Patients in a phase 2b trial kept losing weight after switching to monthly dosing of Pfizer’s GLP-1 receptor agonist, providing early validation of the drugmaker’s $10 billion bet on Metsera.
A phase 2a trial of NMD Pharma’s…
A phase 2a trial of NMD Pharma’s rare disease prospect ignaseclant has missed its primary endpoint. But, with patients improving on multiple secondary endpoints, the biotech is accelerating development of the drug candidate.
GSK is trimming its R&D team,…
GSK is trimming its R&D team, a move expected to affect fewer than 50 workers in the U.K. and fewer than 70 staffers in the U.S.
Novo Nordisk’s GLP-1/amylin…
Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had previously laid out for
H1 CEO Ariel Katz shares how AI,…
H1 CEO Ariel Katz shares how AI, regulation and pricing shifts are changing clinical trials and commercialization.
Wave Life Sciences has the fate of…
Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not to take over development of WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency (AATD),
Daiichi Sankyo’s development of…
Daiichi Sankyo’s development of ADCs continues to hit turbulence. The company has experienced two latest hiccups: the discontinuation of internal development of a next-wave candidate featuring its second ADC platform, and yet another delay for